News

Version v2 of our SaaS platform released!

We are happy to announce that Mind the Byte has released the new v2 version of our SaaS platform for computational drug discovery! In this new version you will find updated AI algorithms and databases, new technologies and an improvement of the User Experience (UX)....

New alliance with IGTP to computationally model immune responses

Mind the Byte is partnering with Germans Trias i Pujol Research Institute (IGTP) to work on the characterization and binding analysis of an immunostimulant agent. This is known to trigger T-cell activation, which is crucial for the initiation and...

New target of Metformin revealed

Metformin, the first drug chosen to be tested in a clinical trial aimed to target the biology of aging per se, has been clinically exploited for decades in the absence of a complete understanding of its therapeutic targets or chemical determinants. Now,...

A new therapy proves effective against brain metastasis

A study published in Nature Medicine by a team led by researchers at the Spanish National Cancer Research Centre (CNIO), with the participation of Mind the Byte, shows that the administration of silibinin in patients with brain metastasis reduces lesions...

Alfons Nonell-Canals, Young Entrepreneur Award finalist

Mind the Byte CEO and founder, Alfons Nonell-Canals, has been chosen as one of three finalists vying for the 2017 Young Entrepreneur Award awarded by the Independent Association of Young Entrepreneurs of Catalonia (AIJEC). The other finalists are Gerard...

Finalist of the Bio-IT World Best of Show awards

We are pleased to announce the Bio-IT has selected Mind the Byte as one of the 2018 Best of Show finalists. The Best of Show Awards offers exhibitors at the Bio-IT World Conference & Expo an opportunity to showcase their new products. A team of expert...